Extensively Drug-Resistant Tuberculosis, Burkina Faso

Nuccia Saleri, Gisèle Badoum, Martial Ouedraogo, Sary M. Dembélé, Rachel Nacanabo, Victor Bonkoungou, Daniela Cirillo, Gabriele Pinsi, and Alberto Matteelli

Because data from countries in Africa are limited, we measured the proportion of extensively drug-resistant (XDR) tuberculosis (TB) cases among TB patients in Burkina Faso for whom retreatment was failing. Of 34 patients with multidrug-resistant TB, 2 had an XDR TB strain. Second-line TB drugs should be strictly controlled to prevent further XDR TB increase.

Extensively drug-resistant (XDR) tuberculosis (TB) represents an emerging public health problem worldwide, characterized by alarming fatality rates regardless of patients’ HIV status (1,2). XDR TB is defined as in vitro resistance to isoniazid and rifampin plus any fluoroquinolone and at least 1 injectable drug (capreomycin, kanamycin, or amikacin).

Since 2006, a total of 49 countries have reported XDR TB (3). Data from countries in Africa are scant, with the exception of South Africa, where the prevalence is high, especially among HIV-infected persons (3). However, these data may reflect diagnostic limitations rather than the true epidemiologic situation. In Burkina Faso, a low-income country in western Africa, TB prevalence is 226 new cases per 100,000 population (4), and multidrug-resistant (MDR) TB is estimated at 2.1% among new patients with smear-positive TB (5). During a systematic search for MDR TB among TB patients in Burkina Faso for whom a retreatment regimen was failing, we documented 2 cases of XDR TB.

The Study

In 2006, a program was established by the National Tuberculosis Program, Burkina Faso; the University of Brescia, Italy; and the San Raffaele Scientific Institute, Italy, to perform drug-susceptibility testing (DST) on sputum samples from patients listed in the Burkina Faso Chronic TB Register. To be included in this register, patients must have experienced treatment failure after standard and retreatment regimens consisting of the following (in order): 2 months of streptomycin, rifampin, isoniazid, pyrazinamide, and ethambutol; then 1 month of rifampin, isoniazid, pyrazinamide, and ethambutol; and then 5 months of rifampin, isoniazid, and ethambutol. Failure was defined as a persistently positive sputum smear after 5 months of treatment. All patients were informed and consented to the study.

From January 2006 through March 2009, a total of 156 patients with chronic TB were registered in Burkina Faso. For 88 patients, sputum samples were collected before treatment with second-line drugs; for 48, they were collected at 1–12 months of treatment with second-line drugs. Samples were immediately frozen and stored at –20°C before being transferred on dry ice for culture and first-line DST at the University of Brescia and for second-line DST and genotyping at San Raffaele Scientific Institute. Samples were cultured on an MGIT 960 automated system (Becton Dickinson Microbiology Systems, Cockeysville, MD, USA) according to the manufacturer’s instructions. DST to first- and second-line drugs was performed on all Mycobacterium tuberculosis isolates by classic dilution method.

M. tuberculosis was isolated from 50 samples; 45 patients had not yet taken second-line drugs and 5 had. Of the 50 isolates, 34 (68%) were confirmed as MDR TB, 29 from untreated patients and 5 from treated patients. We identified 2 cases of XDR TB (5.9% of all MDR TB cases): 1 patient was sampled at month 24 of treatment with second-line drugs, and 1 was initially classified as having MDR TB before his disease progressed to XDR TB during follow-up treatment with second-line drugs.

Patient 1 was a 33-year-old man who was born in Côte d’Ivoire, moved to Burkina Faso in 2000, and received a diagnosis of smear-positive pulmonary TB in July 2003. He received an 8-month standard treatment regimen (including 6 months of continuation with isoniazid and ethambutol). Treatment was directly observed during the first 2 months. In January 2004, his treatment was classified as failed, and he immediately started a standard retreatment regimen. Because his sputum did not clear by month 5, the patient was registered as a patient with chronic TB. During 2004, he traveled throughout Mali and Côte d’Ivoire. Back in Burkina Faso in January 2005, he was admitted to the reference national hospital for patients with chronic TB. His HIV test result was negative. At this time neither culture and DST nor a standard second-line drug regimen approved by the...
Mechanisms of emergence of XDR TB in Burkina Faso differ from those in South Africa, where most identified XDR TB cases are primarily resistant, occur among HIV-infected patients, and result from exposure in the hospital or the community (7). Because each of the 2 XDR TB patients in Burkina Faso reported long-term stays in neighboring countries, we believe that response to the MDR TB challenge should be based on regional rather than national strategies.

Our study supports current policies for strictly controlled introduction of second-line drugs and the current Green Light Committee strategy that requires demonstration of compliance with guidelines for proper management of MDR TB before granting access to second-line drugs (8). Stakeholders and TB program managers in Africa should be reminded that the main reasons for development of resistance in TB are poor patient adherence to treatment regimen, inappropriate drug prescription, irregular drug supply, and poor drug quality (9). When these factors occur with use of second-line TB drugs, the result will be XDR TB.

Rapid adoption of a programmatic approach to management of MDR TB (6) is warranted in Burkina Faso and probably other countries in western Africa. In countries without effective programs for community or outpatient care of patients with MDR TB, hospital care in reference centers enables appropriate follow-up during the initial phases of treatment. In this context, implementation of appropriate infection control measures should rank high among program priorities (10).

Acknowledgments

We thank Boncoungou Kadiatou, Bambara Médard, Ouedraogo Georges, Ouedraogo Moumini, Koala Théophile, Koumbem Mariam, Tamboura Djibril, Combary Adjima, Saouadogo Tandaogo, and Dembélé Jean for their help in obtaining data. We also thank Hain Lifescience, Nehren, Germany, for providing GenoType MTBDrplus assay free of charge.

This study was partially funded by an Italian Cooperation/World Health Organization Support to High Burden Countries grant to D.C. The study was also partially funded by the Italian Cooperation/World Health Organization/University of Brescia contract APW HQ/05/446637. The study was performed in the framework of the agreement for technical support requested by the National Tuberculosis Programme of Burkina Faso according to the Green Light Committee recommendation to provide better care for patients with chronic TB.

Dr. Saleri is a physician in the National Tuberculosis Program, Burkina Faso. Her main research interests include tuberculosis and tuberculosis/HIV co-infection.
References


Address for correspondence: Alberto Matteelli, Institute of Infectious and Tropical Diseases, University of Brescia, Piazza Spedali Civili 1, 25100 Brescia, Italy; email: matteelli@med.unibs.it